B2B Transparency Report

Reviewed by Saphe: 01/26/2023
Producer: Mighty Fine Manufacturing
Product Name: Perfect Plant – 10mg Delta 9 Tiger Blood Shot
Batch ID: (RE80)(E43)H48
Product Expiration: 07/10/2024

Seed/Clone
- Verified Lab COA
- Licensed Producer
- Certified Seed

01. Seed/Clone Documentation
Supplier Name: Confidential
Lab Name: N/A

Biomass
- Verified Lab COA
- Licensed Producer
- Cultivation Practices

02. Biomass Documentation
Supplier Name: Confidential
Lab Name: Internal

Extract
- Verified Lab COA
- Licensed Producer
- Extraction Practices

03. Extract Documentation
Supplier Name: Confidential
Lab Name: Gobi Hemp, CO

04. Final Formulation
Supplier Name: Confidential
Lab Name: Gobi Hemp, CO

License
- Colorado Industrial Hemp: Yes

Testing Documentation
Potency: Yes
Pesticides: Yes
Heavy Metals: Yes
Mycotoxins: Yes
Mold/Microbials: Yes

Certifications
- USDA Organic: Yes
- GMP Certified: Yes
- Kosher: Yes
- ISO 9001:2015: Yes
- FDA Registered: Yes
- Non-GMO: Yes

Reviewed by Saphe: 01/26/2023
Producer: Mighty Fine Manufacturing
Product Name: Perfect Plant – 10mg Delta 9 Tiger Blood Shot
Batch ID: (RE80)(E43)H48
Product Expiration: 07/10/2024

© Saphe Inc. 2024
www.saphe.io
Gobi Hemp - Certificate of Analysis

**Manifest:** 2401180002  
**Sample ID:** 1A-GHEMP-2401180002-0005  
**Sample Name:** 10mg Delta 9 Tiger Blood Shot - (RE80)(E43)H48  
**Sample Type:** Infused (edible)  
**Client ID:** CID-50292  
**Client:** Mighty Fine Manufacturing  
**Address:** 423 Houston Street, Suite 100, Nashville, TN 37203  
**Test Performed:** Potency  
**Report No:** P-2401180002-V1  
**Receive Date:** 2024-01-18  
**Test Date:** 2024-01-18  
**Report Date:** 2024-01-18  
**Sample Condition:** Good  
**Method Reference:** GH-OP-06

**Scope:** The content of 21 cannabinoids was determined by an in-house developed method certified by CDPHE for solvent extraction followed by High Performance Liquid Chromatography with Diode Array Detection.

<table>
<thead>
<tr>
<th>Cannabinoids</th>
<th>mg/unit</th>
<th>mg/g</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total THC</td>
<td>9.79</td>
<td>0.11</td>
</tr>
<tr>
<td>Total CBD</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>Total CBG</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>Total Cannabinoids</td>
<td>9.79</td>
<td>0.11</td>
</tr>
<tr>
<td>Total THC:CBD Ratio</td>
<td>NA</td>
<td></td>
</tr>
<tr>
<td>Net Weight (g)</td>
<td>90.00</td>
<td></td>
</tr>
</tbody>
</table>

Total CBD = CBD + (CBDA x 0.877); Total CBG = CBG + (CBGA x 0.877)
Total THC = Δ⁹ THC + (THCA x 0.877)

Lab Comments:

Michael McNulty Lead Analyst  
Date  
2024-01-18

This report has been prepared by Gobi Hemp Laboratory exclusively for our Client and their Authorized Representatives. All analytical work is conducted in accordance with a mutually agreed upon scope of work and the terms and conditions as expressed in the Gobi Hemp Laboratory Service Agreement. This report is not to be reproduced in whole or in part without prior written approval. The results shown on this report relate only to the samples submitted to the laboratory. Estimated Uncertainty available upon request. Only cannabinoids included in the table above are ISO/IEC 17025:2017 accredited.

- Gobi Hemp •  
- 3940 Youngfield St. • Wheat Ridge CO 80033 • ISO/IEC 17025-2017 Accredited • (303) 955-4934 •
Gobi Hemp
Analytical Report - Certificate of Analysis

Manifest: 2401180002
Sample ID: 1A-GHEMP-2401180002-0005
Sample Name: 10mg Delta 9 Tiger Blood Shot - (RE80)(E43)H48
Sample Type: Infused (edible)
Client ID: CID-50292
Client: Mighty Fine Manufacturing
Address: 423 Houston Street, Suite 100, Nashville, TN 37203

Test Performed: Hemp Lab
Intended Use: Oral Consumption or Audited Product
Report No: MT-2401180002-V1
Receive Date: 2024-01-18
Test Date: 2024-01-19
Report Date: 2024-01-22
Sample Condition: Good
Method Reference: GH-OP-17

Scope: Arsenic, Cadmium, Lead and Mercury were determined by an Inductively Coupled Plasma Mass Spectrometer (ICP-MS) using an in-house developed method.

<table>
<thead>
<tr>
<th>Elemental Impurities</th>
<th>LOD (ppm)</th>
<th>LOQ (ppm)</th>
<th>Parts Per Million (ppm)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Arsenic</td>
<td>0.007</td>
<td>0.025</td>
<td>ND</td>
</tr>
<tr>
<td>Cadmium</td>
<td>0.003</td>
<td>0.01</td>
<td>ND</td>
</tr>
<tr>
<td>Lead</td>
<td>0.003</td>
<td>0.01</td>
<td>ND</td>
</tr>
<tr>
<td>Mercury</td>
<td>0.0009</td>
<td>0.003</td>
<td>ND</td>
</tr>
</tbody>
</table>

ND - not detected; T - trace; ULOQ - upper limit of quantitation; LOD - limit of detection; LOQ - limit of quantitation

Lab Comments:

This report has been prepared by Gobi Hemp Laboratory exclusively for our Client and their Authorized Representatives. All analytical work is conducted in accordance with a mutually agreed upon scope of work and the terms and conditions as expressed in the Gobi Hemp Laboratory Service Agreement. This report is not to be reproduced in whole or in part without prior written approval. The results shown on this report relate only to the samples submitted to the laboratory. Estimated Uncertainty available upon request. Sample(s) tested at Gobi Analytical.

Jon Person Director of Communication

2024-01-22
Gobi Hemp
Microbial Contaminant Report - CDPHE Certified
Certificate of Analysis

Manifest: 2401180002
Sample ID: 1A-GHEMP-2401180002-0005
Sample Name: 10mg Delta 9 Tiger Blood Shot - (RE80)(E43)H48
Sample Type: Infused (edible)
Client ID: CID-50292
Client: Mighty Fine Manufacturing
Address: 423 Houston Street, Suite 100, Nashville, TN 37203

Test Performed: Hemp Lab
Report No: M-2401180002-V1
Receive Date: 2024-01-18
Test Date: 2024-01-19
Report Date: 2024-01-23
Sample Condition: Good

Scope: Contaminant testing for the identified pathogens *Salmonella spp.* and *Shiga Toxin Virulence Genes, O26, O45, O103, O111, O121, O145 and O157:H7 serogroups of Escherichia coli* (STEC) was performed through Polymerase Chain Reaction (PCR) presumptive experimentation, and confirmed through cultural methodology where applicable. Results for *Salmonella spp.* and STEC are represented as a negative or positive determination, a negative result indicating no detection of the respective contaminant.

Total Yeast and Mold Count (TYMC)/Total Aerobic Count (TAC)/Total Coliform Count (TCC) were determined through 3M™ Petrifilm™ plating technology. The TYMC/TAC/TCC is represented as a count in colony forming units per gram (cfu/g).

<table>
<thead>
<tr>
<th>Microbial Contaminants</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td><em>Salmonella spp.</em></td>
<td>ND</td>
</tr>
<tr>
<td>STEC</td>
<td>ND</td>
</tr>
<tr>
<td>Total Yeast and Mold</td>
<td>&lt;100 CFU/g</td>
</tr>
<tr>
<td>Total Aerobic</td>
<td>&lt;100 CFU/g</td>
</tr>
<tr>
<td>Total Coliform</td>
<td>&lt;100 CFU/g</td>
</tr>
</tbody>
</table>

STEC - *shiga toxin-producing Escherichia coli*; TYMC - total yeast and mold count; TAC - Total Aerobic Count; TCC - Total Coliform Count; NT - Not Tested;
*CDPHE Certified Result

Lab Comments:

This report has been prepared by Gobi Hemp Laboratory exclusively for our Client and their Authorized Representatives. All analytical work is conducted in accordance with a mutually agreed upon scope of work and the terms and conditions as expressed in the Gobi Hemp Laboratory Service Agreement. This report is not to be reproduced in whole or in part without prior written approval. The results shown on this report relate only to the samples submitted to the laboratory. Estimated Uncertainty available upon request.
Gobi Hemp - Certificate of Analysis

Manifest: 2401180002
Sample ID: 1A-GHEMP-2401180002-0005
Sample Name: 10mg Delta 9 Tiger Blood Shot - (RE80)(E43)H48
Sample Type: Infused (edible)
Client ID: CID-50292
Client: Mighty Fine Manufacturing
Address: 423 Houston Street, Suite 100, Nashville, TN 37203

Test Performed: Hemp Lab
Report No: PE-2401180002-V3
Receive Date: 2024-01-18
Test Date: 2024-01-25
Report Date: 2024-01-26
Sample Condition: Good
Method Reference: GH-OP-11

Scope: The content of 60 pesticides were quantified using liquid chromatography coupled to multiple mass spectrometry (LC-MS2) equipped with electrospray ionization (ESI) in positive mode after sample extraction using methodology based on AOAC 2007 and EN 15662 standard procedures. Identification was based on the retention time of each compound and the product mass generated using single reaction monitoring (SRM), and quantitation was determined using external standard calibration.

<table>
<thead>
<tr>
<th>Analyte</th>
<th>Reporting Level µg/g</th>
<th>µg/g</th>
<th>Analyte</th>
<th>Reporting Level µg/g</th>
<th>µg/g</th>
</tr>
</thead>
<tbody>
<tr>
<td>Avermectin B1a</td>
<td>0.1</td>
<td>ND</td>
<td>Hexythiazox</td>
<td>0.1</td>
<td>ND</td>
</tr>
<tr>
<td>Acephate</td>
<td>0.1</td>
<td>ND</td>
<td>Imidacloprid</td>
<td>0.1</td>
<td>ND</td>
</tr>
<tr>
<td>Acetamiprid</td>
<td>0.1</td>
<td>ND</td>
<td>Imidacloprid</td>
<td>0.1</td>
<td>ND</td>
</tr>
<tr>
<td>Aldicarb</td>
<td>0.1</td>
<td>ND</td>
<td>Kresoxim Methyl</td>
<td>0.1</td>
<td>ND</td>
</tr>
<tr>
<td>Azoxystrobin</td>
<td>0.1</td>
<td>ND</td>
<td>Malathion</td>
<td>0.1</td>
<td>ND</td>
</tr>
<tr>
<td>Bifenazole</td>
<td>0.1</td>
<td>ND</td>
<td>Metalaxyl</td>
<td>0.1</td>
<td>ND</td>
</tr>
<tr>
<td>Benethrin</td>
<td>0.1</td>
<td>ND</td>
<td>Methiocarb</td>
<td>0.1</td>
<td>ND</td>
</tr>
<tr>
<td>Bosalid</td>
<td>0.1</td>
<td>ND</td>
<td>Methomyl</td>
<td>0.1</td>
<td>ND</td>
</tr>
<tr>
<td>Captan</td>
<td>0.1</td>
<td>ND</td>
<td>Methomyl</td>
<td>0.1</td>
<td>ND</td>
</tr>
<tr>
<td>Carbaryl</td>
<td>0.1</td>
<td>ND</td>
<td>MGK-264</td>
<td>0.1</td>
<td>NT</td>
</tr>
<tr>
<td>Carboutran</td>
<td>0.1</td>
<td>ND</td>
<td>Myclobutanil</td>
<td>0.1</td>
<td>ND</td>
</tr>
<tr>
<td>Chlorantraniliprole</td>
<td>0.1</td>
<td>ND</td>
<td>Oxamyl</td>
<td>0.1</td>
<td>ND</td>
</tr>
<tr>
<td>Chloride</td>
<td>0.1</td>
<td>ND</td>
<td>Paclobutrazol</td>
<td>0.1</td>
<td>ND</td>
</tr>
<tr>
<td>Chlopyrifos</td>
<td>0.1</td>
<td>ND</td>
<td>Pentachloronitrobenzene</td>
<td>0.1</td>
<td>ND</td>
</tr>
<tr>
<td>Clocifenazine</td>
<td>0.1</td>
<td>ND</td>
<td>Permethrin*</td>
<td>0.1</td>
<td>ND</td>
</tr>
<tr>
<td>Coumaphos</td>
<td>0.1</td>
<td>ND</td>
<td>Imidan(Phosmet)</td>
<td>0.1</td>
<td>ND</td>
</tr>
<tr>
<td>Baythroid (Cyfluthrin)*</td>
<td>0.1</td>
<td>NT</td>
<td>Piperonyl Butoxide</td>
<td>0.1</td>
<td>ND</td>
</tr>
<tr>
<td>Cypermethrin*</td>
<td>0.1</td>
<td>NT</td>
<td>Propiconazole</td>
<td>0.1</td>
<td>ND</td>
</tr>
<tr>
<td>Dichlorvos</td>
<td>0.1</td>
<td>ND</td>
<td>Propoxur</td>
<td>0.1</td>
<td>ND</td>
</tr>
<tr>
<td>Diazinon</td>
<td>0.1</td>
<td>ND</td>
<td>Pyrethrin*</td>
<td>0.1</td>
<td>ND</td>
</tr>
<tr>
<td>Dimethoate</td>
<td>0.1</td>
<td>ND</td>
<td>Pyriproxifen</td>
<td>0.1</td>
<td>ND</td>
</tr>
<tr>
<td>Dimethomorph*</td>
<td>0.1</td>
<td>ND</td>
<td>Spinetoram</td>
<td>0.1</td>
<td>ND</td>
</tr>
<tr>
<td>Prophos</td>
<td>0.1</td>
<td>ND</td>
<td>Spinosad*</td>
<td>0.1</td>
<td>ND</td>
</tr>
<tr>
<td>Etofenprox</td>
<td>0.1</td>
<td>ND</td>
<td>Spriomesfesin</td>
<td>0.1</td>
<td>ND</td>
</tr>
<tr>
<td>Etoxazole</td>
<td>0.1</td>
<td>ND</td>
<td>Sprotetramat</td>
<td>0.1</td>
<td>ND</td>
</tr>
<tr>
<td>Fenhexamid</td>
<td>0.1</td>
<td>ND</td>
<td>Spiroxamine</td>
<td>0.1</td>
<td>ND</td>
</tr>
<tr>
<td>Fenoxycarb</td>
<td>0.1</td>
<td>ND</td>
<td>Tebuconazole</td>
<td>0.1</td>
<td>ND</td>
</tr>
<tr>
<td>Fenpyroximate</td>
<td>0.1</td>
<td>ND</td>
<td>Thiacloprid</td>
<td>0.1</td>
<td>ND</td>
</tr>
<tr>
<td>Fipronil</td>
<td>0.1</td>
<td>ND</td>
<td>Thiamethoxam</td>
<td>0.1</td>
<td>ND</td>
</tr>
<tr>
<td>Flonicamid</td>
<td>0.1</td>
<td>ND</td>
<td>Trifloxystrobin</td>
<td>0.1</td>
<td>ND</td>
</tr>
<tr>
<td>Fludioxocil</td>
<td>0.1</td>
<td>ND</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

NT - not tested; ND - not detected above Reporting Level; T – trace; * Total of Isomers

Lab Comments:

This report has been prepared by Gobi Hemp Laboratory exclusively for our Client and their Authorized Representatives. All analytical work is conducted in accordance with a mutually agreed upon scope of work and the terms and conditions as expressed in the Gobi Hemp Laboratory Service Agreement. This report is not to be reproduced in whole or in part without prior written approval. The results shown on this report relate only to the samples submitted to the laboratory. Estimated Uncertainty available upon request.

Gobi Hemp
3940 Youngfield St. • Wheat Ridge CO 80033 • ISO/IEC 17025:2017 Accredited • (303) 955-4934
Gobi Hemp
Analytical Report - Certificate of Analysis

Manifest: 2401180002
Sample ID: 1A-GHEMP-2401180002-0005
Sample Name: 10mg Delta 9 Tiger Blood Shot - (RE80)(E43)H48
Sample Type: Infused (edible)
Client ID: CID-50292
Client: Mighty Fine Manufacturing
Address: 423 Houston Street, Suite 100, Nashville, TN 37203

Test Performed: Hemp Lab
Report No: R-2401180002-V1
Receive Date: 2024-01-18
Test Date: 2024-01-18
Report Date: 2024-01-26
Sample Condition: Good
Method Reference: GH-OP-16

Scope: Ochratoxin and Total Aflatoxin were quantified using liquid chromatography coupled to multiple mass spectrometry (LC-MS/MS) equipped with electrospray ionization (ESI) in positive mode after sample extraction. Identification was based on the retention time of each compound and the product mass generated using single reaction monitoring (SRM). Quantitation was determined using external calibration.

<table>
<thead>
<tr>
<th>Mycotoxins</th>
<th>LOD (ppm)</th>
<th>LOQ (ppm)</th>
<th>Reporting Limits (ppm)</th>
<th>Parts Per Million (ppm)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aflatoxin G2</td>
<td>0.0019</td>
<td>0.0050</td>
<td>0.0050</td>
<td>ND</td>
</tr>
<tr>
<td>Aflatoxin G1</td>
<td>0.0011</td>
<td>0.0050</td>
<td>0.0050</td>
<td>ND</td>
</tr>
<tr>
<td>Aflatoxin B2</td>
<td>0.0017</td>
<td>0.0050</td>
<td>0.0050</td>
<td>ND</td>
</tr>
<tr>
<td>Aflatoxin B1</td>
<td>0.0015</td>
<td>0.0050</td>
<td>0.0050</td>
<td>ND</td>
</tr>
<tr>
<td>Ochratoxin A</td>
<td>0.0033</td>
<td>0.0050</td>
<td>0.0050</td>
<td>ND</td>
</tr>
</tbody>
</table>

ND - not detected; T - trace; ULOQ - upper limit of quantitation; LOD - limit of detection; LOQ - limit of quantitation

Lab Comments:
This report has been prepared by Gobi Hemp Laboratory exclusively for our Client and their Authorized Representatives. All analytical work is conducted in accordance with a mutually agreed upon scope of work and the terms and conditions as expressed in the Gobi Hemp Laboratory Service Agreement. This report is not to be reproduced in whole or in part without prior written approval. The results shown on this report relate only to the samples submitted to the laboratory. Estimated Uncertainty available upon request.